Literature DB >> 7971998

Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

C H Freudenreich1, K N Kreuzer.   

Abstract

Type II topoisomerases are the targets of several classes of chemotherapeutic agents that stabilize an intermediate of the catalytic cycle with the enzyme covalently linked to cleaved DNA. We have used 3-azido-AMSA [4'-(3-azido-9-acridinylamino)methanesulfon-m-anisidide], a photo-activatible analog of the inhibitor m-AMSA [4'-(9-acridinylamino)methanesulfon-m-anisidide], to localize the inhibitor binding site in a cleavage complex consisting of an oligonucleotide substrate and the bacteriophage T4 type II DNA topoisomerase. Upon photoactivation, the inhibitor covalently attached to the substrate only in the presence of topoisomerase. Sites of inhibitor attachment were detected by primer-extension analysis and by piperidine-induced cleavage of the covalently modified substrate. 3-Azido-AMSA reacted with bases immediately adjacent to the two phosphodiester bonds cleaved by the enzyme. Therefore, topoisomerase creates or stabilizes preferential binding sites for the inhibitor precisely at the two sites of DNA cleavage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7971998      PMCID: PMC45155          DOI: 10.1073/pnas.91.23.11007

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

2.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

3.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

Authors:  L L Shen; W E Kohlbrenner; D Weigl; J Baranowski
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

Review 4.  Mechanistic aspects of DNA topoisomerases.

Authors:  A Maxwell; M Gellert
Journal:  Adv Protein Chem       Date:  1986

Review 5.  Inhibitors of DNA topoisomerases.

Authors:  K Drlica; R J Franco
Journal:  Biochemistry       Date:  1988-04-05       Impact factor: 3.162

6.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

7.  Novel blunt-end addition reactions catalyzed by DNA polymerase I of Escherichia coli.

Authors:  J M Clark; C M Joyce; G P Beardsley
Journal:  J Mol Biol       Date:  1987-11-05       Impact factor: 5.469

8.  Sites of reaction of Escherichia coli DNA gyrase on pBR322 in vivo as revealed by oxolinic acid-induced plasmid linearization.

Authors:  D Lockshon; D R Morris
Journal:  J Mol Biol       Date:  1985-01-05       Impact factor: 5.469

9.  Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

Authors:  G Capranico; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

10.  Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons.

Authors:  Y H Hsiang; L F Liu
Journal:  J Biol Chem       Date:  1989-06-15       Impact factor: 5.157

View more
  18 in total

1.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.

Authors:  Y Takebayashi; P Pourquier; A Yoshida; G Kohlhagen; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 3.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

4.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

5.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

Review 6.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

7.  Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites.

Authors:  Y Kwok; Q Zeng; L H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

8.  In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites.

Authors:  H Gmünder; K Kuratli; W Keck
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

9.  The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage.

Authors:  B Gatto; S Richter; S Moro; G Capranico; M Palumbo
Journal:  Nucleic Acids Res       Date:  2001-10-15       Impact factor: 16.971

10.  Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.

Authors:  Nathalie Vilain; Monika Tsai-Pflugfelder; Audrey Benoit; Susan M Gasser; Didier Leroy
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.